In malignant B cells from Chronic Lymphocytic Leukemia (CLL) and Splenic Marginal Zone Lymphoma (SMZL), LAIR1 was heterogeneously expressed (Figure 3) in comparison with the level of expression in normal B cells, with two dichotomic groups of patients defined as patients with B tumoral cells expressing LAIR1 and patients with B malignant cells that did not express LAIR1. Here, LAIR1 is linked to splenic marginal zone lymphoma.